Always verify pricing and state availability on the provider's website before signing up.How our reviews work →
GoodRx (Foundayo + Zepbound KwikPen) vs Zealthy
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
8.4
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies★★★★☆4.2
Starting at $149/mo
FoundayoZepbound KwikPenBrandSelf-Pay Discount Card
Visit GoodRx (Foundayo + Zepbound KwikPen) →4.8
Zealthy
Best for not currently recommended — listed for transparency and reader awareness only★★☆☆☆2.4
Starting at $286/mo
CompoundedSemaglutideTirzepatide
Visit Zealthy →Side-by-Side Comparison
| Feature | GoodRx (Foundayo + Zepbound KwikPen) | Zealthy |
|---|---|---|
| Overall Score | ✓8.4/10 | 4.8/10 |
| Starting Price | ✓$149/mo | $286/mo |
| Editorial Rating | ✓4.2 ★ /5 | 2.4 ★ /5 |
| Features | ✓6 features | 3 features |
| States Available | ✓50 | 34 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 2 warnings |
Pros & Cons
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
Zealthy
Pros
- ✓34 states served — meaningful nationwide footprint
- ✓Asynchronous model removes friction for patients comfortable without a synchronous video visit
- ✓Independent licensed prescribers retain full clinical authority
Cons
- ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
- ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
- ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
- ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
- ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
- ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
- ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
Our Verdict
Winner: GoodRx (Foundayo + Zepbound KwikPen)Score: 8.4/10
GoodRx (Foundayo + Zepbound KwikPen) edges out Zealthy with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.